{"id":"benzathine-penicilllin-g","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Allergic reaction (rash, urticaria)"},{"rate":"0.004-0.04","effect":"Anaphylaxis"},{"rate":"null","effect":"Jarisch-Herxheimer reaction"},{"rate":"null","effect":"Local injection site reactions (pain, induration)"},{"rate":"1-3","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3989515","moleculeType":"Small molecule","molecularWeight":"981.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benzathine penicillin G is a long-acting formulation of penicillin that penetrates bacterial cell walls and irreversibly inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan strands. This disruption of cell wall integrity leads to bacterial cell lysis and death. The benzathine salt provides sustained release, allowing for prolonged therapeutic levels and less frequent dosing compared to aqueous penicillin formulations.","oneSentence":"Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:56.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Syphilis (primary, secondary, and latent)"},{"name":"Rheumatic fever prophylaxis"},{"name":"Group A Streptococcal infections"},{"name":"Acute rheumatic fever prevention"}]},"trialDetails":[{"nctId":"NCT05069974","phase":"PHASE3","title":"Alternative Antibiotics for Syphilis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2021-10-14","conditions":"Early Latent Syphilis, Primary Syphilis, Secondary Syphilis","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Benzathine Penicilllin G","genericName":"Benzathine Penicilllin G","companyName":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","companyId":"fundaci-n-fls-de-lucha-contra-el-sida-las-enfermedades-infecciosas-y-la-promoci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking. Used for Syphilis (primary, secondary, and latent), Rheumatic fever prophylaxis, Group A Streptococcal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}